{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-036504","form_type":"8-K","ticker":"ETON","cik":"0001710340","company_name":"Eton Pharmaceuticals, Inc.","filed_at":"2024-12-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.305937+00:00","generated_at":"2026-05-29T09:56:15.563817+00:00","sec_items":["8.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Eton Pharmaceuticals appoints Ipek Erdogan-Trinkaus as CCO; cites Increlex closing and ET-400 launch","bullets":["Ipek Erdogan-Trinkaus appointed Chief Commercial Officer, effective December 3, 2024.","She previously served as GM of Pediatric Endocrinology at Tolmar, leading the FENSOLVI® launch.","CEO Sean Brynjelsen highlights role at a critical time with Increlex closing in late-December and ET-400 launch in early 2025.","Erdogan-Trinkaus brings rare disease commercial experience from Tolmar and other health/wellness companies."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-036504","json":"https://secwatch.observer/filing/0001437749-24-036504.json","markdown":"https://secwatch.observer/filing/0001437749-24-036504.md","text":"https://secwatch.observer/filing/0001437749-24-036504.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1710340/000143774924036504/0001437749-24-036504-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1710340/000143774924036504/eton20241127_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T09:56:15.563817+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}